Patents by Inventor Jianliang Lu

Jianliang Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12238220
    Abstract: A blockchain-based workflow node certification method includes a certification party establishing a general workflow template. The general workflow template includes a plurality of workflow nodes each having an audit attribute for indicating whether the workflow node needs to be certified. The certification party establishes a general data template based on the general workflow template, and the general data template and the general workflow template are instantiated. A current workflow node is acquired in the instantiated general workflow template, and whether the current workflow node needs to be certified-is determined, based on the audit attribute. Certification, if needed, is performed by a centralized certification party, and users can create and modify transaction processes as needed to meet the needs of changeable transactions. By combining central certification with blockchain certification deposition, the security of workflow node process implementation and the privacy of specific data are ensured.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: February 25, 2025
    Assignee: Shanghai NanoJClean Technology Co., Ltd.
    Inventors: Duanxin Lu, Qiangle Geng, Bangya Ma, Jianliang Gu
  • Publication number: 20250051345
    Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder. ADHD, Phelan-Mc-Dermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease. Brugada Syndrome. Short QT syndrome, or early repolarization syndrome.
    Type: Application
    Filed: December 12, 2022
    Publication date: February 13, 2025
    Inventors: Simon Krautwald, Jianliang Lu, James Anthony Neef, Hye-Yeon Park, Tejaskumar Pankajbhai Pathak, Amir Masoud Sadaghiani, Xilin Zhou
  • Publication number: 20240331144
    Abstract: A novel medical image generation approach synthesizes thin-cut computerized tomography (CT) images from thick-cut CT ones as inputs. First thick-cut CT images are obtained by maximizing the pixel-wise intensity of five or more than five continuous thin-cut ones after image registration. Second, the obtained thick-cut CT images are fed into a generator block which adopts an encoder-decoder architecture, where each thick-cut image is encoded into low-dimensional embedding space before decoding into multiple thin-cut ones. Third, a discriminator focuses on distinguishing original real thin-cut images from synthetic thin-cut images. An adversarial mechanism between the generator and discriminator causes the discriminator's output to provide an effective gradient update of the network parameters for the generator to increasingly improve the generator's ability to synthesize higher-quality thin-cut images and in turn promotes the discriminator's discriminating capability.
    Type: Application
    Filed: July 18, 2022
    Publication date: October 3, 2024
    Applicants: Versitech Limited, The Education University of Hong Kong
    Inventors: Man Fung YUEN, Gilbert Chiu Sing LUI, Jianliang LU, Keith Wan Hang CHIU, Wai Kay Walter SETO, Philip Leung Ho YU
  • Publication number: 20240312009
    Abstract: A three dimensional classification system for recognizing cross-sectional images automatically contains a processor that executes: (1) rescaling of a plurality of cross-sectional images; and feeding the rescaled plurality of cross-sectional images into two branches; (2) feeding the rescaled plurality of cross-sectional images into a first branch for performing a plurality of convolutions on the rescaled plurality of cross-sectional images directly to learn features for distinguishing phases; (3) feeding the rescaled plurality of cross-sectional images into a second branch for reducing resolution, and then performing a plurality of convolutions on the reduced resolution plurality of cross-sectional images to learn features for distinguishing phases; and (4) concatenating convolutional output channels from the two branches to fuse global and local features, on which two fully-connected layers are stacked as a classifier to recognize cross-sectional volumetric images accurately and quickly.
    Type: Application
    Filed: July 6, 2023
    Publication date: September 19, 2024
    Applicants: Versitech Limited, The Education University of Hong Kong
    Inventors: Keith Wan Hang CHIU, Wai Kay Walter SETO, Gilbert Chiu Sing LUI, Jianliang LU, Man Fung YUEN, Philip Leung Ho YU
  • Publication number: 20120302547
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I) wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Application
    Filed: August 8, 2012
    Publication date: November 29, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Macklin Brian Arnold, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu
  • Patent number: 8299061
    Abstract: This invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof; as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: October 30, 2012
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Thomas James Beauchamp, Emily Jane Canada, Erik James Hembre, Jianliang Lu, John Robert Rizzo, John Mehnert Schaus, Qing Shi
  • Patent number: 8263772
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (1): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: September 11, 2012
    Assignee: Eli Lilly and Company
    Inventors: Macklin Brian Arnold, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu
  • Patent number: 8101764
    Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Albert Kudzovi Amegadzie, Yen Dao, Kevin Matthew Gardinier, David Joseph Garmene, Steven James Green, Erik James Hembre, Jianliang Lu, Patrick Gianpietro Spinazze
  • Publication number: 20110144091
    Abstract: This invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof; as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.
    Type: Application
    Filed: December 7, 2010
    Publication date: June 16, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Macklin Brian Arnold, Thomas James Beauchamp, Emily Jane Canada, Erik James Hembre, Jianliang Lu, John Robert Rizzo, John Mehnert Schaus, Qing Shi
  • Patent number: 7897789
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: July 6, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
  • Patent number: 7772425
    Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: August 10, 2010
    Assignee: Eli Lilly and Company
    Inventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
  • Patent number: 7750184
    Abstract: The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: July 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Robert Peter Gajewski, Charles David Jones, Jared Harris Linebarger, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
  • Publication number: 20100076065
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Application
    Filed: July 6, 2009
    Publication date: March 25, 2010
    Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
  • Patent number: 7612067
    Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: November 3, 2009
    Assignee: Eli Lilly and Company
    Inventors: Heather Janelle Barbosa, Elizabeth Aaron Collins, Chafiq Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Richard Duane Johnston, Jianliang Lu, Michael John Rupp, Takako Takakuwa, Richard Craig Thompson
  • Patent number: 7601850
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-thiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: October 13, 2009
    Assignee: Eli Lilly and Company
    Inventors: Karl Robert Dahnke, Robert Peter Gajewski, Charles David Jones, Jared Harris Linebarger, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Todd Parker Simard, Ying Kwong Yee, Emilio Enrique Bunel, Ryan Edward Stites
  • Patent number: 7595345
    Abstract: The present invention relates to novel, non-secosteroidal, hydroxyl substituted, carbon-linked diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Sunil Nagpal, Tianwei Ma, Ying Kwong Yee
  • Publication number: 20090227604
    Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Application
    Filed: May 22, 2009
    Publication date: September 10, 2009
    Inventors: Emilio Enrique Bunel, Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
  • Patent number: 7582775
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: September 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jianliang Lu, Tainwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Ying Kwong Yee, Michael John Rupp
  • Patent number: 7579488
    Abstract: The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: August 25, 2009
    Assignee: Eli Lilly and Company
    Inventors: Jianliang Lu, Tianwei Ma, Sunil Nagpal, Quanrong Shen, Alan M. Warshawsky, Jason Matthew Ochoada, Ying Kwong Yee
  • Patent number: 7566803
    Abstract: The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: July 28, 2009
    Assignee: Eli Lilly and Company
    Inventor: Jianliang Lu